Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
JS006 / Shanghai Junshi Biosci
NCT05757492: Study to Evaluate Safety and PK of CHS-006 in Combination With Toripalimab in Patients With Advanced Solid Tumors	Terminated	1/2	22	US	CHS-006 (anti-TIGIT), JS006, toripalimab (anti-PD-1), CHS-007, TAB001, JS001	Coherus Biosciences, Inc., Medpace, Inc., Shanghai Junshi Bioscience Co., Ltd.	Advanced Solid Tumor, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma	07/24	07/24
NCT05061628: The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor	Recruiting	1	176	RoW	JS006 as Monotherapy, JS006 in combination with Toripalimab	Shanghai Junshi Bioscience Co., Ltd.	Advanced Tumors	08/23	09/24
NCT05650203: A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies	Withdrawn	1	254	NA	JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006	Shanghai Junshi Bioscience Co., Ltd.	Primary Condition: Advanced Tumors	10/25	12/26